Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Use of Biologic Agents in Cutaneous Emergencies
Description
In this presentation, Dr. Leb Wall discusses the role of biologic agents in cutaneous emergencies, specifically focusing on conditions such as generalized pustular psoriasis (GPP), psoriatic erythroderma, pyoderma gangrenosum, bullous pemphigoid, and toxic epidermal necrolysis. He highlights the high mortality rates associated with GPP and emphasizes the urgency of treatment due to the compromised skin barrier leading to sepsis. A significant advancement in treatment is the use of an antibody against the interleukin 36 receptor, which has shown dramatic effectiveness in clinical trials. Dr. Wall underscores the importance of rapid intervention in emergency situations and shares compelling case studies that demonstrate the life-saving potential of timely treatment with biologics like spasolamab. He critiques other biologics, expressing that they are often too slow for emergency use. The talk also addresses potential complications, including the rare paradoxical reactions seen with drugs like dupilumab, explaining how misdiagnoses can occur. He concludes by discussing treatment strategies for other severe skin conditions, reinforcing the critical need for accurate diagnoses and appropriate, timely therapies in dermatologic emergencies.
View moreConclusions
- Generalized pustular psoriasis (GPP) has a higher mortality rate than the general population, with infections being a primary cause of death.
- Spesolimab, an IL-36 receptor antagonist, shows rapid efficacy in treating GPP, with significant reductions in pustule counts observed as early as one week post-infusion.
- High-dose spesolimab administration significantly reduces the risk of GPP flares, demonstrating an 84% lower risk compared to placebo.
- Treatment with spesolimab led to quick clinical improvement, suggesting that early intervention in GPP is critical to reducing complications and mortality.
- There is a potential risk of infections associated with biologic treatments, although the overall safety profile of spesolimab appears favorable after more extensive use.
- Biologics previously used for psoriasis may not be adequate in emergency cases; spesolimab is faster and more effective for acute GPP management.
- The development of subcutaneous formulations of spesolimab can enhance treatment accessibility and long-term management strategies for patients prone to recurrent GPP flares.
- Gottlieb AB, et al. EADV 2023, P2442. Sponsored by Boehringer Ingelheim
- Green MS, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996;34(5 Pt 2):911-4
- Bakri FG, et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Scand J Infect Dis 2007;39:457-60
- Pouessel G, et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Pediatr Dermatol 2007;24:401-4
- Sharkey MP, et al. Staphylococcal scalded skin syndrome complicating acute generalized pustular psoriasis. Australas J Dermatol 2002;43:199-201
- Marrakchi S, et al; A. N Engl J Med. 2011; 365:620-8.
- Bachelez H, et al. EADV 2021, FC08.05. Sponsored by Boehringer Ingelheim
- Burns M, Orlowski M, Ho-Pham H, Elston C, Elewski B. SKIN,2023; 7:585-588.
- Lebwohl M, et al. WCD 2023. Late-breaking oral; Morita A, et al. Lancet 2023;402:1541-51. Sponsored by Boehringer Ingelheim
- Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Van Voorhees AS; National Psoriasis Foundation Medical Board. J Am Acad Dermatol. 2010;62(4):655-62.
- Deepak P, et al. Am J Gastroenterol. 2013;108:99-105.
- Ao S, Gao X, Zhan J, Ai L, Li M, Su H, Tang X, Chu C, Han J, Wang F. J Am Acad Dermatol. 2022:S0190-9622(22)00171-2.